Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
J Med Genet. 2012 Jul;49(7):420-1. doi: 10.1136/jmedgenet-2012-100941. Epub 2012 Jun 15.
Validation of a recent finding linking a rare variant in TP53 to the risk of glioma, the most common primary brain tumour, is reported here. This study genotyped the single nucleotide polymorphism (SNP) rs78378222 in 566 glioma cases and 603 controls. The variant 'C' allele (with an allelic frequency of 1.1% in controls) was associated with a 3.5-fold excess in glioma risk (odds ratio 3.54; p=0.0001). Variant carriers had significantly improved survival (hazard ratio 0.52; p=0.009) when compared to non-carriers. The rs78378222 SNP is the first confirmed rare susceptibility variant in glioma. Results may shed light on the aetiology and progression of these tumours.
本研究旨在验证最近发现的 TP53 罕见变异与最常见的原发性脑肿瘤——神经胶质瘤之间的关联。该研究对 566 例神经胶质瘤病例和 603 例对照进行了单核苷酸多态性 (SNP) rs78378222 的基因分型。在对照组中,变异等位基因“C”(等位基因频率为 1.1%)与神经胶质瘤风险增加 3.5 倍相关(比值比 3.54;p=0.0001)。与非携带者相比,变异携带者的生存显著改善(风险比 0.52;p=0.009)。rs78378222 SNP 是首个经证实的神经胶质瘤罕见易感性变异。该结果可能阐明了这些肿瘤的发病机制和进展。